Synaptogenix News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

18.07.24	Synaptogenix Partners With LSU Health New Orleans To Study PUFA Analogs To Treat Spinal Cord Injury (RTTNews)
19.12.23	Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders (PR Newswire)
06.12.23	Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's (PR Newswire)
02.11.23	Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology (PR Newswire)
26.09.23	Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Di... (PR Newswire)
07.09.23	Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study (PR Newswire)
19.07.23	Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis (PR Newswire)
13.07.23	Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience (PR Newswire)
07.03.23	Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities (PR Newswire)
16.12.22	Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease (PR Newswire)
18.11.22	Synaptogenix Announces $15 Million Private Placement with Existing Investors (PR Newswire)
19.10.22	Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022 (PR Newswire)
28.09.22	Synaptogenix Welcomes Lecanemab Phase 3 Trial Results (PR Newswire)
12.08.22	Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network (PR Newswire)
26.07.22	Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data (PR Newswire)
21.07.22	Synaptogenix Announces Corporate Update Conference Call (PR Newswire)
20.07.22	Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data (PR Newswire)
17.05.22	Synaptogenix to Present at the Cell Symposium (PR Newswire)
19.04.22	Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial (PR Newswire)
05.04.22	New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease (PR Newswire)
29.03.22	Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit (PR Newswire)
22.03.22	Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum (PR Newswire)
15.03.22	Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022) (PR Newswire)
23.02.22	Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis (PR Newswire)
01.02.22	Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients (PR Newswire)
28.09.21	Synaptogenix Announces Participation at the Benzinga Healthcare Small Cap Conference (PR Newswire)
10.09.21	Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Kuehne+Nagel Int	208.40	2.26 %	K V
Nestle	78.18	1.06 %	K V
CieFinRichemont	177.45	0.88 %	K V
ABB	50.48	0.80 %	K V
Novartis	97.49	0.57 %	K V
Part Grp Hldg	1’408.50	0.14 %	K V
Holcim	95.84	-0.02 %	K V
UBS Group	30.28	-0.10 %	K V
Roche Hldg G	289.70	-0.31 %	K V
Givaudan	3’814.00	-0.37 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Synaptogenix Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten